阿立哌唑与奋乃静治疗精神分裂症的临床疗效与安全性比较  

Comparison of efficacy and safety between aripiprazole and perphenazine in treatment of patients with schizophrenia

作　　者：王来海[1] 石玉中[1] 王新法[1] 王新友[1] 张瑞岭[1] 

机构地区：[1]新乡医学院第二附属医院,河南新乡453002

出　　处：《中国新药与临床杂志》2011年第2期115-118,共4页Chinese Journal of New Drugs and Clinical Remedies

摘　　要：目的比较阿立哌唑与奋乃静治疗精神分裂症的临床疗效及安全性。方法 94例精神分裂症患者随机分为阿立哌唑组和奋乃静组各47例,分别口服阿立哌唑10～30mg·d^(-1)或奋乃静20～40mg·d^(-1)治疗,疗程为8wk。于基线及服药wk 2、4、6、8末,采用阳性和阴性症状量表(PANSS)评定疗效,副反应量表(TESS)评定不良反应。结果 2组治疗wk 2末起PANSS总分均较治疗前有显著下降(P<0.01),阿立哌唑组PANSS阳性症状、阴性症状和一般病理症状因子分与治疗前比较均有非常显著下降(P<0.01),奋乃静组阴性症状因子分与治疗前比较无显著差异(P>0.05)。治疗wk 8末阿立哌唑组PANSS总分减分率为(68±11)%,奋乃静组为(67±12)%;阿立哌唑组显效率为70%,奋乃静组为68%,2组疗效无显著差异(P>0.05)。阿立哌唑组不良反应发生率较奋乃静组少(26%vs.89%,P<0.01)。结论阿立哌唑治疗精神分裂症疗效与奋乃静相当,不良反应较奋乃静少,能更有效改善阴性症状。AIM To compare the clinical efficacy and safety of aripiprazole and perphenazine in treatment of the patients with schizophrenia. METHODS In this 8-wk randomized study, 94 patients diagnosed with schizophrenia were divided randomizely into aripiprazole （10 - 30 mg·d^-1） group and perphenazine （20 - 40 mg·d^-1） group with 47 in each group. The efficacy and safety were assessed with the Positive and Negative Syndrome Scale （PANSS） and Treatment Emergent Symptom Score （TESS） from baseline and at wk 2, 4, 6, 8 of treatment, respectively. RESULTS Compared with baseline, the total scores of PANSS in both groups decreased significantly after 2 wk treatment （P 〈 0.01 ） , and the scores of positive, negative and general pathological symptoms in the aripiprazole group decreased significantly （P 〈 0.01 ）, while there was no change in negative symptom scores in the perphenazine group （P 〉 0.05） . The decreasing rate on PANSS in the aripiprazole group was （68 ± 11）% and that of the perphenazine group was （67 ± 12）%, and the obvious effective rates were 70% and 68% respectively with no significant difference in efficacy between the two groups （P 〉 0.05） . Adverse reactions were fewer in the aripiprazole group （26%） than that of the perphenazine group （89%）, P 〈 0.01. CONCLUSION Aripiprazole is equivalent to perphenazine in treating schizophrenia and it can improve negative symptoms effectively with more safety and less adverse reactions.

关 键 词：精神分裂症 阿立哌唑 奋乃静 治疗结果 安全性 

分 类 号：R971.4[医药卫生—药品]